


Postoperative Myocardial Infarction: Diagnosis and Management




Todd M. Brown, MD, MSPH

Chief Fellow

Division of Cardiovascular Diseases

December 9, 2008









UA

NSTEMI

STEMI





Pathophysiology

Table 3. Causes of UA/NSTEMI*

Thrombus or thromboembolism, usually arising on disrupted or eroded plaque

- Occlusive thrombus, usually with collateral vessels†
- Subtotally occlusive thrombus on pre-existing plaque
- Distal microvascular thromboembolism from plaque-associated thrombus

Thromboembolism from plaque erosion

- Non-plaque-associated coronary thromboembolism

Dynamic obstruction (coronary spasm‡ or vasoconstriction) of epicardial and/or microvascular vessels

Progressive mechanical obstruction to coronary flow

Coronary arterial inflammation

Secondary UA

Coronary artery dissection§

Pathophysiology

- Other mechanisms of myocardial ischemia in the postoperative patient
 - Fluid mobilization which increases strain on vulnerable myocardium
 - Coronary perfusion pressure = $DBP - LVEDP$
 - Pro-thrombotic state associated with surgery
 - Catecholamine surges
 - Post-operative pain
 - Tachycardia and hypertension

Patients at Greatest Risk

- High Risk Clinical Features
 - Unstable coronary syndromes
 - Unstable or severe angina
 - Recent MI
 - Decompensated CHF
 - Significant arrhythmias
 - Severe valvular heart disease
- Other Clinical Risk Factors
 - History of ischemic heart disease
 - History of CHF
 - History of cerebrovascular disease
 - Diabetes mellitus
 - Renal insufficiency

Procedural Risk

Table 4. Cardiac Risk* Stratification for Noncardiac Surgical Procedures

Risk Stratification	Procedure Examples
Vascular (reported cardiac risk often more than 5%)	Aortic and other major vascular surgery Peripheral vascular surgery
Intermediate (reported cardiac risk generally 1% to 5%)	Intraperitoneal and intrathoracic surgery Carotid endarterectomy Head and neck surgery Orthopedic surgery Prostate surgery
Low† (reported cardiac risk generally less than 1%)	Endoscopic procedures Superficial procedure Cataract surgery Breast surgery Ambulatory surgery

*Combined incidence of cardiac death and nonfatal myocardial infarction.

†These procedures do not generally require further preoperative cardiac testing.

Pathophysiology

- Surgical procedures at greatest risk
 - Vascular procedures
 - Major abdominal, thoracic, and head and neck surgeries
- Patients at greatest risk
 - History of CAD or CHF
- Circumstances associated with increased risk of postoperative MI
 - Postoperative hypotension, new intraoperative ST changes, intraoperative blood loss requiring transfusion

Pathophysiology

- Post-operative myocardial ischemia
 - the strongest predictor of perioperative cardiac morbidity
 - is rarely accompanied by pain
 - may go untreated until overt symptoms of cardiac failure develop
 - Clinical heart failure, arrhythmias, hypotension, confusion

Pathophysiology

- Time course of myocardial infarction
 - 94% occur by postoperative day 2
 - 44% on the day of surgery
 - 34% on postoperative day 1
 - 16% on postoperative day 2

Surveillance

- Clinically low-risk patients undergoing low-risk surgery
 - Only if symptoms warrant
- Intermediate or high risk patients undergoing intermediate or high risk surgery
 - EKG's should be done at baseline, immediately after the procedure and daily for 2 days
 - Routine troponin measurements should also be done

Diagnostic and Therapeutic Approach to ACS

- Initial stabilization and inpatient management
- Risk Stratification
 - Early identification of those patients who are likely to benefit from revascularization (PCI, CABG)
- Risk factor management and secondary prevention
- Symptom control

Initial Stabilization

- Initial therapies in patients with ACS
 - Antiplatelet agents
 - Aspirin, clopidogrel, glycoprotein IIb/IIIa inhibitors
 - Anticoagulation
 - Heparin, LMWH, Fondaparinux, Bivalirudin
 - Anti-Ischemic Therapy
 - Beta-blockers, Nitrates, CCB
 - Statins
 - Ace Inhibitors
 - Oxygen
 - Blood

General Anti-Ischemic Measures for all Patients with UA/NSTEMI

1. Oxygen
 - if sat <90% (Class I)
 - all patients (Class IIa)

2. Nitroglycerin
 - SL PRN for chest pain (Class I)
 - IV for persistent ischemia, HF symptoms, or hypertension (Class I)
 - IV NTG should not preclude the use of mortality reducing therapies (BB, Ace I) (Class I)
 - Nitrates contraindicated with recent use of sildenafil (24 hours), tadalafil (48%), or vardenafil (unknown time duration) (Class III)

3. Morphine
 - for chest pain despite NTG administration (Class IIa)

4. Beta Blockers
 - PO in those without: HF symptoms, low-output state, increased risk of cardiogenic shock, and those with relative contraindications to BB (AV interval >240 msec, 2nd/3rd degree AV Block, asthma/RAD) (Class I)
 - IV for the treatment of hypertension or tachycardia in the absence of above listed contraindications (Class IIa)

General Anti-Ischemic Measures for all Patients with UA/NSTEMI

5. Calcium Channel Blockers
 - non-dihydropyridine CCB's in those intolerant of BB (Class I)

6. Ace Inhibitors
 - PO in those with: EF <40 or pulmonary congestion (Class I)
 - PO in everyone (Class IIa)
 - IV ace inhibitors are contraindicated (Class III)

7. Angiotensin Receptor Antagonists
 - PO in those intolerant of ace inhibitors (Class I)

Risk Stratification

- You have a choice between invasive and non-invasive testing
- Invasive testing (Coronary Angiography) is generally preferred in the following situations:
 - STEMI
 - Positive cardiac enzymes (NSTEMI)
 - Refractory angina
 - Hemodynamic or electrical instability
 - Recent stents
 - Prior CABG
 - Those who initially are managed conservatively and have a high risk non-invasive study

